Who benefits from the COVID pill Paxlovid? what study found

Who benefits from taking a COVID-19 antiviral?  One study found that Pfizer's treatment pill Paxlovid benefited older adults in preventing hospitalization and death.

Who benefits from taking a COVID-19 antiviral? One study found that Pfizer’s treatment pill Paxlovid benefited older adults in preventing hospitalization and death.


There are some COVID-19 antiviral treatments out there, but that doesn’t mean everyone who takes them will benefit.

Pfizer’s PaxLovid Pill Diet Is a Favorite COVID-19 Antiviral Treatment In the US, according to the National Institutes of Health. It is intended for patients aged 12 years and above who have mild to moderate COVID-19 infection and are at risk of developing severe illness.

In a new study, Paxlovid showed no benefit for adults under 65 when it came to stopping serious COVID-19 consequences Hospitalization resulted in death, according to findings published August 24 in the New England Journal of Medicine.

However, for adults 65 years of age and older, hospitalization and death rates were significantly lower in patients who did not take Paxclovid, compared with the study in Israel notes.

A Pfizer spokesperson declined a request for comment from McClatchy News.

The research involved examining the medical records of 109,254 patients aged 40 and older in Israel who were eligible for Paxlovid treatment during an Omicron boom between January and March. Of these individuals, 3,902 took antivirals.

Paxlovid has been prescribed President Joe Biden And most recently, First Lady Jill Biden to COVID-19, according to ABC News. Both experienced a “rebound” case after treatment, meaning they tested positive for the virus following a negative test result following PaxLovid treatment.

More on Paxlovid Findings

The Food and Drug Administration has Paxlovid. approved emergency use authorization To be taken in oral tablet form in late December. It is not for people hospitalized with COVID-19.

According to the NIH, treatment consists of two antiviral drug pills, nirmatrelavir and ritonavir, which describes Paxlovid as “ritonavir-boosted nirmatrelvir,

In the study, among patients 65 years of age and older who took nirmatalavir after testing positive for the virus, there were 14.7 COVID-19 hospitalizations for every 100,000 “person-days,” or a full work day.

According to the research, hospitalization rates were higher for patients 65 years of age and older who did not receive COVID-19 treatment. Notably, there were 58.9 hospitalizations per 100,000 person-days due to the virus.

The study found that when it came to patients between the ages of 40 and 64, PaxLovid did not offer much benefit in terms of preventing COVID-19 hospitalizations.

For people in this age group who received treatment, there were 15.2 COVID-19 hospitalizations per 100,000 person-days, according to the research, compared to 15.8 hospitalizations per 100,000 person-days for those treated. had not been.

,paxlovid It will remain important for people at highest risk of severe COVID-19, such as seniors and those with compromised immune systems,” Dr. David Boulware of the University of Minnesota told the Associated Press.

“But for the majority of Americans who are eligible now, it really doesn’t have much of a benefit.”

Other COVID Antivirals

Is the only FDA-approved COVID-19 antiviral remdesivirAccording to NIH. It is the second preferred COVID-19 antiviral treatment after Paxlovid and is administered intravenously.

The NIH says remdesivir is for “high-risk, non-hospitalized patients with mild to moderate COVID-19.”

When Paxlovid or remdesivir is not available, these are the two COVID-19 antiviral treatment options recommended by the NIH:

  • babetelovimabi

  • molanupiravir

The health agency recommends these COVID-19 antivirals as treatments against:

in America, covid-19 case According to the Centers for Disease Control and Prevention, until August 26 the numbers are decreasing after increasing in the previous summer months.

Julia Marnin is a McClatchy National real-time reporter who covers the Southeast and Northeast while living in New York. She is an alumna of The College of New Jersey and joined McClatchy in 2021. Previously, she has written for Newsweek, Modern Luxury, Gannett and more.

Leave a Comment